MA53739A - Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés - Google Patents

Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés

Info

Publication number
MA53739A
MA53739A MA053739A MA53739A MA53739A MA 53739 A MA53739 A MA 53739A MA 053739 A MA053739 A MA 053739A MA 53739 A MA53739 A MA 53739A MA 53739 A MA53739 A MA 53739A
Authority
MA
Morocco
Prior art keywords
parkinson
disease
treatment
composition
related disorders
Prior art date
Application number
MA053739A
Other languages
English (en)
Inventor
Thomas N Chase
Kathleen E Clarence-Smith
Original Assignee
Chase Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chase Therapeutics Corp filed Critical Chase Therapeutics Corp
Publication of MA53739A publication Critical patent/MA53739A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053739A 2018-09-25 2019-09-24 Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés MA53739A (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862735997P 2018-09-25 2018-09-25
US201862785602P 2018-12-27 2018-12-27
US201862785605P 2018-12-27 2018-12-27
US201862785606P 2018-12-27 2018-12-27
US201962787614P 2019-01-02 2019-01-02
US201962817274P 2019-03-12 2019-03-12
US201962840539P 2019-04-30 2019-04-30

Publications (1)

Publication Number Publication Date
MA53739A true MA53739A (fr) 2021-12-29

Family

ID=69949689

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053739A MA53739A (fr) 2018-09-25 2019-09-24 Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés

Country Status (11)

Country Link
US (1) US20210338652A1 (fr)
EP (1) EP3856168A4 (fr)
JP (1) JP2022502479A (fr)
KR (1) KR20210107621A (fr)
CN (1) CN113164424A (fr)
AU (1) AU2019346543A1 (fr)
BR (1) BR112021008087A2 (fr)
CA (1) CA3121184A1 (fr)
IL (1) IL282562A (fr)
MA (1) MA53739A (fr)
WO (1) WO2020068832A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111588692B (zh) * 2020-05-23 2022-11-22 常州市第四制药厂有限公司 盐酸普拉克索口服溶液

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273809A1 (fr) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Utilisation d'antagonistes du recepteur nk-1 dans le traitement des diskynesies
EP1361878A1 (fr) * 2001-02-15 2003-11-19 Neurosearch A/S Traitement de la maladie de parkinson par l'action combinee d'un compose a activite neurorophique et un compose a activite dopamine
AU2015213396B2 (en) * 2009-09-18 2018-02-15 Chase Pharmaceuticals Corporation Method and composition for treating Alzheimer-type dementia
KR101890317B1 (ko) * 2010-12-16 2018-08-22 선오비온 파마슈티컬스 인코포레이티드 설하 필름
WO2018039159A1 (fr) * 2016-08-22 2018-03-01 Chase Pharmaceuticals Corporation Combinaison d'antagoniste de m2 muscarinique
AU2018243718A1 (en) * 2017-03-27 2019-11-07 Chase Therapeutics Corporation Compositions and methods for treating synucleinopathies

Also Published As

Publication number Publication date
KR20210107621A (ko) 2021-09-01
EP3856168A1 (fr) 2021-08-04
BR112021008087A2 (pt) 2021-08-03
IL282562A (en) 2021-06-30
WO2020068832A1 (fr) 2020-04-02
EP3856168A4 (fr) 2022-07-06
US20210338652A1 (en) 2021-11-04
CA3121184A1 (fr) 2020-04-02
AU2019346543A1 (en) 2021-05-20
CN113164424A (zh) 2021-07-23
JP2022502479A (ja) 2022-01-11

Similar Documents

Publication Publication Date Title
MA53661A (fr) Agonistes du récepteur farnésoïde x pour le traitement d'une maladie
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
MA46052A (fr) Modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques
MA52861A (fr) Méthodes et compositions pour le traitement de l'apnée du sommeil
MA56387A (fr) Dérivés de quinazoline-4-one utiles pour le traitement de maladies et de troubles associés à braf
MA52616A (fr) Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses
MA55148A (fr) Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance
MA49131A (fr) Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
MA52747A (fr) Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
MA47207A (fr) Composés utiles pour le traitement de troubles du tractus digestif
MA56019A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA53252A (fr) Thérapie génique non perturbatrice pour le traitement d'un mma
MA54522A (fr) Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
FR2918282B1 (fr) Medicament pour le traitement de la maladie de parkinson
IL288894A (en) Methods for the assessment and treatment of Alzheimer's disease and their applications
MA53739A (fr) Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés
MA49794A (fr) Composition utilisée dans le traitement prophylactique et thérapeutique de troubles de l'appareil cardiovasculaire
MA49140A (fr) Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
MA54530A (fr) Schémas posologiques pour l'utilisation de ly3154207 dans le traitement de troubles du système nerveux central dopaminergiques
MA50495A (fr) Composés bicycliques à fusion 5,6 et compositions pour le traitement de maladies parasitaires
MA55141A (fr) Composés cyanoaryl-aniline pour le traitement d'affections de la peau
MA56186A (fr) Composés pour le traitement d'une maladie respiratoire